Literature DB >> 4028471

Reversibility of reduced mucociliary clearance in chronic sinusitis.

Y Sakakura, Y Majima, S Saida, K Ukai, Y Miyoshi.   

Abstract

Nasal mucociliary clearance was measured before and after treatment in patients with chronic sinusitis. Nasal mucociliary transit time before the study was greater than 36 min in 8 out of 14 patients who were treated with S-carboxymethylcysteine, and in 9 out of 22 patients who were treated by repeated antral lavage. The nasal mucociliary clearance was significantly improved by both treatment regimens. This may indicate that the malfunction of the nasal mucociliary system is not the cause of chronic sinusitis but an effect of chronic inflammation of the respiratory mucosa.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028471     DOI: 10.1111/j.1365-2273.1985.tb01171.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  4 in total

1.  Cytokine profile in paranasal effusions in patients with chronic sinusitis using the YAMIK sinus catheter with and without betamethasone.

Authors:  Kyosuke Furukido; Sachio Takeno; Tsutomu Ueda; Koji Yajin
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-02-13       Impact factor: 2.503

Review 2.  Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

Authors:  Eleanor James; Cathy Ellis; Ruth Brassington; Sivakumar Sathasivam; Carolyn A Young
Journal:  Cochrane Database Syst Rev       Date:  2022-05-20

3.  Comparison by objective parameters in patients with chronic rhinosinusitis managed medically and surgically (with and without powered instruments).

Authors:  Samarendra Behera; Satyawati Mohindra; Sourabha K Patro; Ashok K Gupta
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

4.  Genetic variation in genes encoding airway epithelial potassium channels is associated with chronic rhinosinusitis in a pediatric population.

Authors:  Michael T Purkey; Jin Li; Frank Mentch; Struan F A Grant; Martin Desrosiers; Hakon Hakonarson; Elina Toskala
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.